CSL Seqirus mini oral: Statin Intolerance – Where are we today?
| Friday, August 7, 2026 |
| 3:15 PM - 3:45 PM |
| Theatrette 7 (Exhibition Hall) |
Details
Statin intolerance - real, perceived, or somewhere in between - remains one of the most contested issues in lipid management. This session will cut through the noise, revisiting modern definitions, the nocebo effect, and why prevalence may be less important than we think. More importantly, it will focus on what to do next: pragmatic, patient-centred strategies to keep lipid-lowering therapy on track. From low-dose statins to combination approaches, the shift toward “statin-sparing” is redefining care. If patients can’t take standard doses, the answer isn’t stopping - it’s adapting.
Speaker
Prof Stephen Nicholls
Director
Victorian Heart Hospital
Statin Intolerance – Where are we today?
3:15 PM - 3:45 PMBiography
Stephen Nicholls, Program Director of Monash Heart, Intensive Care and the Victorian Heart Hospital at Monash Health, and Professor of Cardiology and Director of the Victorian Heart Institute - Monash University.
A preventive cardiologist, his research spans the translational spectrum, focusing on metabolic risk factors in atherosclerosis, plaque imaging, and development of research acceleration platforms to translate discovery into clinical impact. He has secured more than $165 million in research funding and authored over 1,160 peer reviewed manuscripts, book chapters, and conference proceedings.
Professor Nicholls is Immediate Past President of the Cardiac Society of Australia and New Zealand, Past President of the Australian Atherosclerosis Society, and Founding Chair of the Asia Pacific Cardiometabolic Consortium. A Fellow of the Australian Academy of Health and Medical Sciences, received major research awards from leading national and international professional societies, and recognition by Clarivate as one of the World’s Most-Influential Researchers in Clinical Medicine.
